← Back to all trials
Completed
NCT05698641
Efficiency of HFNC Vs NIV in Patient With Acute Type 2 RF
Conditions: Type 2 Respiratory Failure
Sex: All
Ages: 18 Years – 70 Years
Enrollment: 100
Sponsor: Beni-Suef University
Location: Egypt
Summary
Background: In acute hypoxic respiratory failure, high-flow nasal cannula (HFNC) oxygen treatment is gaining popularity.
However, there is just a small body of research to back up the use of HFNC in acute respiratory failure (ARF) with hypercapnia.Aim of study: To evaluate the effectiveness of high-flow nasal cannula (HFNC) in reducing the rate of endotracheal intubation and PCO2 level in adult patients with Acute moderate type II respiratory failure in comparison to noninvasive positive pressure ventilation (NIPPV).Methods : A randomized control trial that was conducted on patients with acute moderate hypercapnic respiratory failure ARF (arterial blood gases pH 7.25-7.35,
PaCO2>45 mmHg) who were admitted to respiratory and medical critical care units from September 2020 through February 2022 and received HFNC or NIV .The endpoint was treatment failure, which was indicated by either invasive ventilation or mortality .
Eligibility Criteria
Inclusion Criteria:• Acute moderate Hypercapnic respiratory failure patients defined by PH: >7.25 and <7.35 and PCO2 >45mmHg who were admitted to icu and received HFNC or NIV-Exclusion Criteria:Patients aged <18 yearsPatients with altered consciousness defined by a Glasgow coma score of >12 points.Hemodynamic instability defined by systolic arterial blood pressure 90 mmHg, mean arterial blood pressure 65 mm Hg, on vasopressor, confusion , chest pain or loss of consciousness )PH>7.25Patients who need immediate endotracheal intubation.Contraindication to NIV (oral and facial trauma, excessive phlegm with poor expectoration ability, vomiting and Epistaxis)Post cardiac arrest patients.
Source: ClinicalTrials.gov (NCT05698641). StuddyBuddy aggregates publicly available trial information.
